Business Cards
November 7, 2011
AICC Supports Jerusalem Medical Technology Seminar
November 8, 2011
Show all

Drug Treatments

Kfar Saba-based developer of new drugs mainly for Parkinson’s disease and Human Papilloma Virus from  integrin-inhibitory activity of novel small tellurium molecules, based on the compounds’ activity in the inhibition of ligand binding to integrins which was demonstrated in both academic and clinical frameworks.  Successfully completed preclinical studies and clinical  trials (Phase II) for several anti-viral indications, and now seeking introduction to pharmaceutical companies for partnership and investment to complete clinical studies.



Comments are closed.